journal article·2021-11-23

Genome-Editing-Mediated Restructuring of Tumor Immune Microenvironment for Prevention of Metastasis

Dongyoon Kim, Yina Wu, Gayong Shim, Yu-Kyoung Oh

ACS Nano· Volume 15· Issue 11
Publisher page

Abstract

Modulating the tumor immune microenvironment to activate immune cells has been investigated to convert cold to hot tumors. Here, we report that metal-lipid hybrid nanoparticle (MLN)-mediated gene editing of transforming growth factor-β (TGF-β) can restructure the tumor microenvironment to an "immune activated" state for subsequent immunotherapy. MLNs with cationic lipids and elemental metallic Au inside were designed to deliver plasmid DNA encoding TGF-β single guide RNA and Cas9 protein (pC9sTgf) and to convert near-infrared light (NIR) to heat. Upon NIR irradiation, MLNs induced photothermal anticancer effects and calreticulin exposure on B16F10 cancer cells. Lipoplexes of pC9sTgf and MLN (pC9sTgf@MLN) provided gene editing of B16F10 cells and in vivo tumor tissues. In mice treated with pC9sTgf@MLNs and NIR irradiation, the tumor microenvironment showed increases in mature dendritic cells, cytotoxic T cells, and interferon-γ expression. In B16F10 tumor-bearing mice, intratumoral injection of pC9sTgf@MLNs and NIR irradiation resulted in ablation of primary tumors. Application of pC9sTgf@MLNs and NIR irradiation prevented the growth of secondarily challenged B16F10 cells at distant sites and B16F10 lung metastasis. Combined TGF-β gene editing and phototherapy is herein supported as a modality for restructuring the tumor immune microenvironment and preventing tumor recurrence.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea

School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea

Funding

Ministry of Health and Welfare · Ministry of Science and ICT, South Korea

References (62)

Show source-provided references
1. 10.1016/j.trecan.2020.02.02210.1016/j.trecan.2020.02.022 ↗
2. 10.1038/s41422-020-0337-210.1038/s41422-020-0337-2 ↗
3. 10.1001/jamanetworkopen.2020.042310.1001/jamanetworkopen.2020.0423 ↗
4. 10.7150/thno.3756810.7150/thno.37568 ↗
5. 10.1016/j.jconrel.2020.08.01610.1016/j.jconrel.2020.08.016 ↗
6. 10.1038/s41565-019-0570-310.1038/s41565-019-0570-3 ↗
7. 10.1002/adma.20180695710.1002/adma.201806957 ↗
8. 10.1002/adma.20180300110.1002/adma.201803001 ↗
9. 10.1038/s41551-020-0549-210.1038/s41551-020-0549-2 ↗
10. 10.1038/nature2549210.1038/nature25492 ↗
11. 10.1016/j.immuni.2019.03.02410.1016/j.immuni.2019.03.024 ↗
12. 10.1080/14728222.2019.163603410.1080/14728222.2019.1636034 ↗
13. 10.1002/adfm.20190662310.1002/adfm.201906623 ↗
14. 10.1021/acsnano.5b0002110.1021/acsnano.5b00021 ↗
15. 10.1016/j.mattod.2018.12.00310.1016/j.mattod.2018.12.003 ↗
16. 10.1038/aps.2017.210.1038/aps.2017.2 ↗
17. 10.1016/j.bbamem.2012.12.00310.1016/j.bbamem.2012.12.003 ↗
18. 10.1016/j.bbamem.2017.06.00310.1016/j.bbamem.2017.06.003 ↗
19. 10.1126/sciadv.160183810.1126/sciadv.1601838 ↗
20. 10.1002/advs.20190047110.1002/advs.201900471 ↗
21. 10.1021/acsbiomaterials.9b0107910.1021/acsbiomaterials.9b01079 ↗
22. 10.1016/j.apsusc.2019.14386410.1016/j.apsusc.2019.143864 ↗
23. 10.1016/j.microc.2018.04.00410.1016/j.microc.2018.04.004 ↗
24. 10.1021/jp111907410.1021/jp1119074 ↗
25. 10.1080/14728222.2020.174456810.1080/14728222.2020.1744568 ↗
26. 10.1172/jci.insight.13397710.1172/jci.insight.133977 ↗
27. 10.1074/jbc.AC119.00755810.1074/jbc.AC119.007558 ↗
28. 10.1038/nature2550110.1038/nature25501 ↗
29. 10.1093/neuonc/now00910.1093/neuonc/now009 ↗
30. 10.14309/ctg.000000000000005610.14309/ctg.0000000000000056 ↗
31. 10.1002/smll.20150291310.1002/smll.201502913 ↗
32. 10.1021/acsnano.9b0527610.1021/acsnano.9b05276 ↗
33. 10.1073/pnas.191222011710.1073/pnas.1912220117 ↗
34. 10.1002/anie.20170868910.1002/anie.201708689 ↗
35. 10.3389/fimmu.2015.0042210.3389/fimmu.2015.00422 ↗
36. 10.1016/j.clinthera.2016.02.02810.1016/j.clinthera.2016.02.028 ↗
37. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
38. 10.1016/j.jconrel.2020.12.04010.1016/j.jconrel.2020.12.040 ↗
39. 10.7150/thno.2407310.7150/thno.24073 ↗
40. 10.1038/ncomms1319310.1038/ncomms13193 ↗
41. 10.1021/acsnano.9b0207110.1021/acsnano.9b02071 ↗
42. 10.1158/1078-0432.CCR-18-112610.1158/1078-0432.CCR-18-1126 ↗
43. 10.1080/02656736.2020.179719010.1080/02656736.2020.1797190 ↗
44. Ran S. · Cancer Res. · 2002 · 62 · 6132
45. 10.1038/s41416-020-01126-710.1038/s41416-020-01126-7 ↗
46. 10.7150/thno.1635810.7150/thno.16358 ↗
47. 10.1038/s41598-020-67325-710.1038/s41598-020-67325-7 ↗
48. 10.1038/s41392-020-00436-910.1038/s41392-020-00436-9 ↗
49. 10.3390/biom911074310.3390/biom9110743 ↗
50. 10.3389/fcell.2020.0060510.3389/fcell.2020.00605 ↗
51. 10.1093/toxsci/kfaa02410.1093/toxsci/kfaa024 ↗
52. 10.1007/s00280-017-3245-510.1007/s00280-017-3245-5 ↗
53. 10.1038/nprot.2013.14310.1038/nprot.2013.143 ↗
54. 10.1016/j.jconrel.2019.02.01210.1016/j.jconrel.2019.02.012 ↗
55. 10.3390/pharmaceutics1112068010.3390/pharmaceutics11120680 ↗
56. 10.3390/pharmaceutics1304049010.3390/pharmaceutics13040490 ↗
57. 10.1039/C9BM01704F10.1039/C9BM01704F ↗
58. 10.1158/0008-5472.CAN-17-033710.1158/0008-5472.CAN-17-0337 ↗
59. 10.1016/j.xpro.2020.10024610.1016/j.xpro.2020.100246 ↗
60. 10.3791/5356510.3791/53565 ↗
61. 10.1016/j.ab.2012.03.00510.1016/j.ab.2012.03.005 ↗
62. 10.1016/j.bbamem.2012.12.00810.1016/j.bbamem.2012.12.008 ↗